Term
|
Definition
| Nitroglycerin, Metorpolol, Alteplase, Morphine, Abciximab, Eptifibatide, Tirofiban, Heparin |
|
|
Term
|
Definition
| Aspirin, Clopidigrel, Prasugrel, Lisinopril, Captopril, Metoprolol, SL Nitroglycerin |
|
|
Term
| Treatment of chest pain; peripheral arterial dilation; slow heart rate; decreases anxiety; decreases myocardial oxygen demand |
|
Definition
|
|
Term
| Hypoxia due to vent/perfusion mismatch; administer to patients with oxygen sat < 90%; reasonable for all patients for first 6 hours |
|
Definition
|
|
Term
| relives ischemia via coronary /peripheral vasodilation; if symptoms persist, IV infusion indicated |
|
Definition
|
|
Term
| produces rapid antithrombotic effect; should be given promptly and continued indefinitely |
|
Definition
|
|
Term
| enhances myocardial salvage; increases diastolic filling time; decreases myocardial oxygen demand |
|
Definition
| early beta blockers ( metoprolol tartrate) |
|
|
Term
| Use in the first 24 hours for STEMI pts with anterior infarct or HF with EFs < 40% |
|
Definition
|
|
Term
| Does not actively lyse but inhibits further thrombogenesis; useful in PCI patients (esp. if renally impaired) |
|
Definition
|
|
Term
| used in PCI patients but avoid in renal impaired or if surgery is planned |
|
Definition
|
|
Term
| direct thrombin inhibitor; preferred in patients with high risk of bleeding |
|
Definition
|
|
Term
| blocks ADP receptors, prevents fibrinogen binding--> decreased platelet adhesion/aggregation |
|
Definition
|
|
Term
| quicker onset and better platelet inhibitors than Clopidogrel but increased risk of bleeding; CI in pts with active bleed, prior stroke or TIA |
|
Definition
|
|
Term
| more rapid onset vs clopidogrel. binds reversibly to P2Y12 platelet receptor |
|
Definition
|
|
Term
|
Definition
| Abciximab, Eptifibatide, Tirofiban |
|
|
Term
| Used in NSTEMI pateitns on UFH with continuing ischemia, inceased troponin, or other high risk factors not previously treated with bivalirudin and not adequately managed with clopidogrel |
|
Definition
|
|
Term
| platelet function returns in up to 15 days |
|
Definition
|
|
Term
| platelet function returns in 4-8 hours |
|
Definition
|
|
Term
| platelet function returns in 4-8 hours |
|
Definition
|
|
Term
| administration of high dose should be initiated or continued in all patients with STEMI and no contraindications |
|
Definition
|
|
Term
|
Definition
| Alteplase, Tenecteplase, Reteplase |
|
|
Term
| naturally occurring enzyme produced by recombinant DNA technology |
|
Definition
|
|
Term
|
Definition
|
|
Term
| very similar to tPA; 2 10U bolus doses 30 minutes apart |
|
Definition
|
|
Term
| give to all patients getting tPA, TNK or r-PA |
|
Definition
|
|
Term
| give loading dose if < 75 years old, no bolus if > 75; duration is 48 hours to 8 days or until revascularized (used adjuctive therapy to fibrinolytics) |
|
Definition
|
|
Term
| avoid if creatnine clearance is < 30 mL; duration up to 8 days (adjunct to fibrinolytics) |
|
Definition
|
|
Term
| prevents ventricular remodeling and development of heart failure (secondary prevention) |
|
Definition
|
|
Term
| helps prevent recurrent MI and sudden death (secondary prevention) |
|
Definition
|
|
Term
| reduces frequency of recurrent events, risk of death and stroke |
|
Definition
|
|
Term
| first line in heart failure patients; shown to decrease mortality (start and continue 3 years in all patients) |
|
Definition
| Metoprolol succinate and carvedilol |
|
|
